Wolfgang Hartwig

Wolfgang Hartwig is currently the Chairman at LTS Lohmann Therapy Systems Corp., Director at Xention Pharma Ltd., Co-Managing Director at URBANA Energiedienste GmbH, Managing Director at Pharma R&D Consulting GmbH, and Professor at the University of Münster.
He previously held positions such as Chief Executive Officer at Minimax GmbH & Co. KG, Vice Chairman-Supervisory Board at Revotar Biopharmaceuticals AG, Chairman-Management Board at LTS LOHMANN.
Therapie-Systeme AG from 2012 to 2016, Director at Millennium Pharmaceuticals, Inc., Director at Onyx Pharmaceuticals, Inc., Director at CureVac SE, Managing Director at Minimax Viking GmbH, Director-Supervisory Board at Axxam SpA in 2012, Non-Executive Director at ario pharma Ltd., Head-International Pharmaceutical Research at Bayer AG, Member-Supervisory Board at 2invest AG from 2010 to 2012, EVP & Head-Global Pharmaceuticals at Bayer Healthcare LLC, Chief Financial Officer at H&R GmbH & Co. KGaA from 2013 to 2015, Principal at Helmholtz-Gemeinschaft Deutscher Forschungszentren eV, and Principal at Bayer Holding Ltd. He obtained a doctorate degree from the University of Gottingen.